Brookline Capital analyst Kumaraguru Raja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating and announces Price Target of $8.
Brookline Capital Initiates Coverage On SAB Biotherapeutics With Buy Rating, Announces Price Target of $8
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.